Abstract
To the nineties the management of amyotrophic lateral sclerosis (ALS) was symptomatic; now exist a medication that stops the progression of the illness. In 1995 the FDA in United States authorized the Riluzol® use in adult patients with ELA.
The action mechanism of the medication is complex and includes inhibition of glutamate delivery, blockade of excitatory amino acids receptors, inactivation of sodium channels voltage dependents, and the stimulation of a dependent G protein transduction.
Riluzol® is well absorbed orally and crosses the blood brain barrier (HEB). Riluzole® is metabolized in the citochrome P-450 and is excreted by glucoronization. Riluzol® 50 mgrs twice a day, enlarges the survival, between six and 24 months, of patients with ALS that do not have important breath shortness (tracheostomy or assisted ventilation), effect evident in bulbar and lower limbs beginning forms.
The medication is safe and its secondary but frequent effects are: asthenia, adynamia and the queasiness. It is recommended control the liver enzymes during the treatment.
References
Rilutek® (Riluzol). Monografía del producto. Rhône- Poulenc Rorer. 1996.
Asmara H et al. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1995; 56: 197-200.
Eisen A et al. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 1993; 20(4): 297-301.
Testa D. Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis. J Neurol 1989; 236: 445-447.
Roquet F et al. Riluzol, Expert Report on the Pharmaco-Toxicological Documentation. Rhône-Poulenc Rorer. 31 Marzo 1995. 42p.
Food and Drug Administration (FDA). Rilutek® (Riluzol) approval. December 12, 1995.
Megard-Navarro I, Leclerc S. Periodic Safety Update Report for Riluzole for the period 13-Dec-2004 to 12-Jun-2005. Sanofi-Synthelabo Recherche. 19-Dec-2005. 42p.
Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of L-glutamate and L-aspartate from slices of hippocampal area CA1. Br J Pharmacol 1991; 104 (Suppl): 240.
Dessi F, Ben-Ari Y, Charriaut-Marlangue C. Riluzole prevents anoxic injury in cultured cerebellar granule neurons. Eur J Pharmacol 1993; 250: 325-328.
Wahl F et al. Effect of Riluzole on focal cerebral ischaemia in rats. Eur J Pharmacol 1993; 230 209-214.
Rilutek® (Riluzol). Información de Prescripción. Grupo sanofi-aventis. Julio 18 de 2005.
Bensimon G et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591.
Lacomblez L et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis/riluzole study group II. Lancet 1996; 347: 1425-1431.
Andersen PM et al. EFNS task force on management of amyotrophic lateral sclerosis: g0uidelines for diagnosing and clinical care of patients and relatives. European Journal of Neurology 2005; 12: 921-938.
Turner MR, et al. Clinical Trials in ALS: An Overview. Seminars in Neurology 2001; 21: 167-175.
Riluzole: búsqueda en www.pubmed.org realizada el 11 de Octubre de 2006.
Greenberg MK et al. Consejos Prácticos en el Tratamiento de ELA con Riluzol: Reporte del Subcomité de Estándares de la Academia Americana de Neurología. Neurology 1997; 49: 657-659.
Miller RG et al. The ALS Patient Care Database: Goals, design, and early results. Neurology 2000; 54: 53-57.
Talbot K. Motor neurone disease. Postgrad Med 2002; 78: 513-519.
Howard RS, Orrell RW. Management of motor neurone disease. Postgrad Med 2002; 78: 736-741.
Miller RG et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4(3): 191-206.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.